Catheters Active Implantable CDMO Market

The increasing prevalence of chronic diseases globally drives the demand for catheters and active implantable devices. Conditions such as cardiovascular diseases, diabetes, and renal disorders necessitate the use of catheters for effective management. In 2024, the Global Catheters and Active Implantable CDMO Market Industry is valued at 7.49 USD Billion, reflecting a growing need for innovative medical devices. As the population ages and lifestyle-related health issues rise, the market is poised for expansion. This trend indicates a sustained demand for advanced catheter technologies, which are essential for patient care and treatment efficacy.

Based on region, the Catheters and Active Implantable CDMO Market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest market share in 2023 and is anticipated to reach during the forecast period. However, Asia-Pacific is projected to grow at the highest CAGR during the forecast period.

The Active Implantable CDMO market in North America is characterized by robust growth driven by technological advancements, a supportive regulatory environment, and increasing healthcare needs. Moreover, sophisticated healthcare infrastructure and substantial investment in research and development, enabling the creation of cutting-edge implantable devices drives the market. Furthermore, opportunities for expansion into emerging markets, the rise of personalized medicine, and the demand for minimally invasive solutions present avenues for growth. Moreover, strategic partnership and collaborations are fueling the demand for active implantable in North America.

For instance, in December 2022, Veranex acquired Fusion Biotec, a company based in Orange, California that specializes in the design and engineering of complicated electromechanical diagnostic and medical equipment. The agreement brings together Veranex's infrastructure and quick development skills with Fusion's rapid concept-to-production capabilities, improving their focus on expediting diagnostic and medical technology solutions for regulatory and commercial success.

The Americas region is followed by Europe, which is further segmented into the Germany, France, UK, Italy, Spain, and Rest of the Europe. The Active Implantable CDMO market in Europe is marked by significant growth potential driven by technological advancements, and rising healthcare needs. Technological advancements in implantable devices—such as next-generation cardiac pacemakers, neurostimulators, and insulin pumps—are propelling demand for specialized manufacturing expertise. The increasing prevalence of chronic diseases, driven by an aging population, further amplifies the need for sophisticated, high-quality implantable solutions.

For instance, according to European Commission, On January 1, 2023, the EU population was anticipated to be 448.8 million individuals, with more than one-fifth (21.3%) of those aged 65 years or older. Opportunities include expanding into emerging regional markets, focusing on personalized medicine, and developing minimally invasive technologies.

Asia-Pacific is expected to witness significant growth and is projected to be the fastest growing region over the forecast period and experiencing robust growth driven by several key factors Rapid advancements in medical technology and increasing investments in healthcare infrastructure across countries like China, India, and Japan are fueling demand for sophisticated implantable devices.

The rising prevalence of chronic diseases, diabetes and an aging population further drive the need for innovative solutions.  For instance, according to National Institutes of Health (NIH), in Dec 2021, Diabetes accounts for approximately 80% of the worldwide disease burden, with Asia accounting for 60% of diabetics. Asia also has six of the top ten countries with the highest diabetes prevalence. Additionally, the region’s growing focus on enhancing healthcare access and affordability creates significant opportunities for CDMOs. Favorable regulatory environments in emerging markets and supportive government initiatives also contribute to market expansion.

Furthermore, strategic partnerships and collaborations with local medical device manufacturers enhance the ability of CDMOs to scale operations and meet the diverse needs of the regional market.

FIGURE 3: CATHETERS AND ACTIVE IMPLANTABLE CDMO MARKET BY REGION 2023 & 2032 (USD BILLION)

The Catheters and Active Implantable CDMO Market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive, with all the players competing to gain maximum market share. Intense competition, frequent changes in government policies, and regulations are key factors that impact market growth. The vendors compete based on cost, product quality, reliability, and aftermarket services.

Product launch and approvals were also observed to expand the company's product portfolio. The growth of prominent industry players is dependent on various factors, such as market conditions, product differentiation and innovation, and pricing strategies. It is also projected that increasing investment by the biopharmaceutical industry associated with Medical Devices like Catheters and Active Implantable Devices will boost the market's growth in the upcoming future. 

Major players in the Catheters and Active Implantable CDMO Market, including Integer Holding Corporation, Heraeus Group, Cirtec, Freudenberg Medical, Veranex, and others are making investments in R&D activities to boost market demand.

Freudenberg Medical is a global Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) with 11 manufacturing sites around the world. They are global specialists in medical technology with over 30 years of experience in medical devices and pharmaceutical applications. They support a wide range of medical and life science customers globally, enhancing its ability to cater to diverse regional and market-specific needs.

In February 2021, Freudenberg Medical has opened a second production facility in Costa Rica. This expansion supports their strategy of being close to customers, offering efficient solutions throughout the device lifecycle, including large-scale, cost-effective manufacturing capabilities. Initial manufacturing operations will begin in early 2025.